Cargando…

Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma

BACKGROUND: We performed subgroup analyses of the AFTER I-O study to clarify the association of time-to-treatment failure (TTF) and discontinuation reason of prior immune-oncology (I-O) therapy, and molecular targeted therapy (TT) regimen with the outcomes of TT after I-O. METHODS: The data of Japan...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Yoshihiko, Kimura, Go, Fukasawa, Satoshi, Numakura, Kazuyuki, Sugiyama, Yutaka, Yamana, Kazutoshi, Naito, Sei, Kaneko, Hirokazu, Tajima, Yohei, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558912/
https://www.ncbi.nlm.nih.gov/pubmed/34350454
http://dx.doi.org/10.1093/jjco/hyab114
_version_ 1784592662557360128
author Tomita, Yoshihiko
Kimura, Go
Fukasawa, Satoshi
Numakura, Kazuyuki
Sugiyama, Yutaka
Yamana, Kazutoshi
Naito, Sei
Kaneko, Hirokazu
Tajima, Yohei
Oya, Mototsugu
author_facet Tomita, Yoshihiko
Kimura, Go
Fukasawa, Satoshi
Numakura, Kazuyuki
Sugiyama, Yutaka
Yamana, Kazutoshi
Naito, Sei
Kaneko, Hirokazu
Tajima, Yohei
Oya, Mototsugu
author_sort Tomita, Yoshihiko
collection PubMed
description BACKGROUND: We performed subgroup analyses of the AFTER I-O study to clarify the association of time-to-treatment failure (TTF) and discontinuation reason of prior immune-oncology (I-O) therapy, and molecular targeted therapy (TT) regimen with the outcomes of TT after I-O. METHODS: The data of Japanese metastatic renal cell carcinoma patients treated with TT after nivolumab (NIVO) (CheckMate 025) or NIVO + ipilimumab (IPI) (CheckMate 214) were retrospectively analyzed. The objective response rates (ORRs), progression-free survival (PFS) and overall survival (OS) of TT after I-O were analyzed by subgroups: TTF (<6 or ≥6 months) and discontinuation reason of prior I-O (progression or adverse events), and TT regimen (sunitinib or axitinib). We also analyzed PFS2 of prior I-O and OS from first-line therapy. RESULTS: The ORR and median PFS of TT after NIVO and NIVO+IPI among the subgroups was 17–36% and 20–44%, and 7.1–11.6 months and 16.3-not reached (NR), respectively. The median OS of TT after NIVO was longer in patients with longer TTF of NIVO and treated with axitinib. Conversely, median OS of TT after NIVO+IPI was similar among subgroups. The median PFS2 of NIVO and NIVO+IPI was 36.7 and 32.0 months, respectively. The median OS from first-line therapy was 70.5 months for patients treated with NIVO and NR with NIVO+IPI. The safety profile of each TT after each I-O was similar to previous reports. CONCLUSIONS: The efficacy of TT after NIVO or NIVO+IPI was favorable regardless of the TTF and discontinuation reason of prior I-O, and TT regimen.
format Online
Article
Text
id pubmed-8558912
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-85589122021-11-02 Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma Tomita, Yoshihiko Kimura, Go Fukasawa, Satoshi Numakura, Kazuyuki Sugiyama, Yutaka Yamana, Kazutoshi Naito, Sei Kaneko, Hirokazu Tajima, Yohei Oya, Mototsugu Jpn J Clin Oncol Original Article BACKGROUND: We performed subgroup analyses of the AFTER I-O study to clarify the association of time-to-treatment failure (TTF) and discontinuation reason of prior immune-oncology (I-O) therapy, and molecular targeted therapy (TT) regimen with the outcomes of TT after I-O. METHODS: The data of Japanese metastatic renal cell carcinoma patients treated with TT after nivolumab (NIVO) (CheckMate 025) or NIVO + ipilimumab (IPI) (CheckMate 214) were retrospectively analyzed. The objective response rates (ORRs), progression-free survival (PFS) and overall survival (OS) of TT after I-O were analyzed by subgroups: TTF (<6 or ≥6 months) and discontinuation reason of prior I-O (progression or adverse events), and TT regimen (sunitinib or axitinib). We also analyzed PFS2 of prior I-O and OS from first-line therapy. RESULTS: The ORR and median PFS of TT after NIVO and NIVO+IPI among the subgroups was 17–36% and 20–44%, and 7.1–11.6 months and 16.3-not reached (NR), respectively. The median OS of TT after NIVO was longer in patients with longer TTF of NIVO and treated with axitinib. Conversely, median OS of TT after NIVO+IPI was similar among subgroups. The median PFS2 of NIVO and NIVO+IPI was 36.7 and 32.0 months, respectively. The median OS from first-line therapy was 70.5 months for patients treated with NIVO and NR with NIVO+IPI. The safety profile of each TT after each I-O was similar to previous reports. CONCLUSIONS: The efficacy of TT after NIVO or NIVO+IPI was favorable regardless of the TTF and discontinuation reason of prior I-O, and TT regimen. Oxford University Press 2021-08-04 /pmc/articles/PMC8558912/ /pubmed/34350454 http://dx.doi.org/10.1093/jjco/hyab114 Text en © The Author(s) 2021. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Tomita, Yoshihiko
Kimura, Go
Fukasawa, Satoshi
Numakura, Kazuyuki
Sugiyama, Yutaka
Yamana, Kazutoshi
Naito, Sei
Kaneko, Hirokazu
Tajima, Yohei
Oya, Mototsugu
Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma
title Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma
title_full Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma
title_fullStr Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma
title_full_unstemmed Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma
title_short Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma
title_sort subgroup analysis of the after i-o study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in japanese patients with metastatic renal cell carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558912/
https://www.ncbi.nlm.nih.gov/pubmed/34350454
http://dx.doi.org/10.1093/jjco/hyab114
work_keys_str_mv AT tomitayoshihiko subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma
AT kimurago subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma
AT fukasawasatoshi subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma
AT numakurakazuyuki subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma
AT sugiyamayutaka subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma
AT yamanakazutoshi subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma
AT naitosei subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma
AT kanekohirokazu subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma
AT tajimayohei subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma
AT oyamototsugu subgroupanalysisoftheafteriostudyaretrospectivestudyontheefficacyandsafetyofsubsequentmoleculartargetedtherapyafterimmuneoncologytherapyinjapanesepatientswithmetastaticrenalcellcarcinoma